Why the study?
Does the addition of isosorbide dinitrate and hydralazine to best conventional therapy improve outcomes in black patients with symptomatic congestive heart failure?
Does the addition of isosorbide dinitrate and hydralazine to best conventional therapy improve outcomes in black patients with symptomatic congestive heart failure?
No takes yet. Share an insight, caveat, or question.
The editorial discusses the A-HeFT trial, which demonstrated that adding isosorbide dinitrate and hydralazine to conventional therapy significantly improves outcomes in black patients with heart failure.
Joshua M. Hare (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: